Last reviewed · How we verify
ATB-1011
ATB-1011 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.
At a glance
| Generic name | ATB-1011 |
|---|---|
| Sponsor | Autotelicbio |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an investigational autotelic biologic from Autotelicbio, ATB-1011 is engineered to leverage self-sustaining or self-directed immune mechanisms. The precise molecular basis remains proprietary, but the approach typically involves engineering biologics that can autonomously regulate their own activity or persistence in response to disease microenvironments.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 (PHASE1)
- Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes (PHASE3)
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATB-1011 CI brief — competitive landscape report
- ATB-1011 updates RSS · CI watch RSS
- Autotelicbio portfolio CI